stockportfolio.pro
Protagonist Therapeutics, Inc. Revenue 2014–2025
Protagonist Therapeutics, Inc. (PTGX) annual revenue by fiscal year, computed from SEC filings.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $46.02M | -89.4% |
| FY 2024 | $434.43M | +624.1% |
| FY 2023 | $60.00M | +125.7% |
| FY 2022 | $26.58M | -2.8% |
| FY 2021 | $27.36M | -4.4% |
| FY 2020 | $28.63M | +12293.1% |
| FY 2019 | $231,000 | -99.3% |
| FY 2018 | $30.93M | +54.1% |
| FY 2017 | $20.06M | — |
| FY 2016 | $0 | — |
| FY 2015 | $0 | — |
| FY 2014 | $0 | — |
Source: Protagonist Therapeutics, Inc. SEC filings — income statement (10-K). Refreshed nightly.
See the full picture for Protagonist Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeProtagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s revenue?
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $46.02M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.